Many of the cancer drugs currently undergoing clinical trials target apoptosis inhibitors (IAPs), since if the levels of IAPs are reduced, tumor cells will be destroyed by the body’s own self-protecting mechanism or by the chemotherapeutic drugs. However, researchers have recently discovered that IAPs also have another life: they control cell migration.